224 related articles for article (PubMed ID: 23128605)
1. Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87.
Kawai S; Kato S; Imai H; Okada Y; Ishioka C
Oncol Rep; 2013 Jan; 29(1):13-20. PubMed ID: 23128605
[TBL] [Abstract][Full Text] [Related]
2. Suppression of FUT1/FUT4 expression by siRNA inhibits tumor growth.
Zhang Z; Sun P; Liu J; Fu L; Yan J; Liu Y; Yu L; Wang X; Yan Q
Biochim Biophys Acta; 2008 Feb; 1783(2):287-96. PubMed ID: 18023290
[TBL] [Abstract][Full Text] [Related]
3. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
4. Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal positioning and autophagic flux of breast cancer cells.
Tan KP; Ho MY; Cho HC; Yu J; Hung JT; Yu AL
Cell Death Dis; 2016 Aug; 7(8):e2347. PubMed ID: 27560716
[TBL] [Abstract][Full Text] [Related]
5. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
Rao VH; Kandel A; Lynch D; Pena Z; Marwaha N; Deng C; Watson P; Hansen LA
Oncogene; 2012 Jun; 31(23):2888-98. PubMed ID: 21986939
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
7. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
9. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
10. Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis.
Kaulfuss S; Burfeind P; Gaedcke J; Scharf JG
Mol Cancer Ther; 2009 Apr; 8(4):821-33. PubMed ID: 19372555
[TBL] [Abstract][Full Text] [Related]
11. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.
Liu J; Lin B; Hao Y; Qi Y; Zhu L; Li F; Liu D; Cong J; Zhang S; Iwamori M
J Exp Clin Cancer Res; 2009 Dec; 28(1):154. PubMed ID: 20003467
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13.
Ye Y; Zhou X; Li X; Tang Y; Sun Y; Fang J
Tumour Biol; 2014 Nov; 35(11):10891-6. PubMed ID: 25085584
[TBL] [Abstract][Full Text] [Related]
15. EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma.
da Rosa MR; Falcão AS; Fuzii HT; da Silva Kataoka MS; Ribeiro AL; Boccardo E; de Siqueira AS; Jaeger RG; de Jesus Viana Pinheiro J; de Melo Alves Júnior S
Tumour Biol; 2014 Nov; 35(11):11107-20. PubMed ID: 25099616
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
17. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of LeY and fucosyltransferase IV correlates with the receptivity of RL95-2 and HEC-1A human uterine epithelial cells.
Liu S; Yang X; Wang J; Wei J; Zhang D; Wang X; Yan Q
Cell Biol Int; 2012 May; 36(5):469-74. PubMed ID: 22145955
[TBL] [Abstract][Full Text] [Related]
19. Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression.
Shan X; Aziz F; Tian LL; Wang XQ; Yan Q; Liu JW
Int J Oncol; 2015 Apr; 46(4):1667-76. PubMed ID: 25672851
[TBL] [Abstract][Full Text] [Related]
20. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
